Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279845 | 0.92 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTHTTTDP1KMT2A | |
| SCHEMBL4276150 | 0.81 | ALDH1A1 (0.62) | SMN1; SMN2MAPTKMT2AKDM4ELMNA | |
| SCHEMBL4279396 | 0.76 | NPY2R (0.43) | SMN1; SMN2MAPTKMT2AKDM4ELMNA | |
| SCHEMBL13658135 | 0.71 | TP53 (0.44) | SMN1; SMN2MAPTHTTKMT2AKDM4E | |
| SCHEMBL4276349 | 0.71 | SMN1; SMN2 (0.58) | SMN1; SMN2HTTKMT2AKDM4ELMNA | |
| SCHEMBL8247543 | 0.70 | MEN1 (0.58) | SMN1; SMN2MAPTHTTKMT2AKDM4E | |
| SCHEMBL20965408 | 0.69 | L3MBTL1 (0.55) | SMN1; SMN2MAPTHTTTDP1KMT2A | |
| SCHEMBL4273078 | 0.69 | LMNA (0.60) | SMN1; SMN2MAPTHTTKMT2AKDM4E | |
| SCHEMBL20965325 | 0.69 | MAPT (0.54) | SMN1; SMN2MAPTHTTTDP1KMT2A | |
| SCHEMBL3093813 | 0.69 | SMN1; SMN2 (0.70) | SMN1; SMN2HTTHSD11B1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1C, CACNA1I | SMN1; SMN2 2531/4885MAPT 786/4885HTT 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.